SCHEMBL5413239

SCHEMBL5413239

COC(=O)c1cc(C)c(NC(C)=O)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.49
SMN1; SMN2 Q16637 4/20 0.46
MAPT P10636 4/20 0.46
NPC1 O15118 5/20 0.43
RAB9A P51151 4/20 0.43
HPGD P15428 3/20 0.43
KMT2A Q03164 3/20 0.43
CDK1 P06493 1/20 0.43
KDM4E B2RXH2 4/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 2/20 0.41
ADRB2 P07550 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21003306 0.86 SMN1; SMN2 (0.55) ALDH1A1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL22691972 0.85 HTT (0.50) ALDH1A1SMN1; SMN2MAPTRAB9AHPGD
SCHEMBL15797599 0.85 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2MAPTRAB9AHPGD
SCHEMBL22999843 0.85 HDAC1 (0.48) ALDH1A1SMN1; SMN2MAPTHPGDKMT2A
SCHEMBL3972158 0.85 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2MAPTHPGDKMT2A
SCHEMBL4259162 0.83 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL12021166 0.83 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2MAPTHPGDKMT2A
SCHEMBL2430255 0.82 KDM4E (0.50) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL29819513 0.82 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL4258095 0.81 KDM4E (0.50) ALDH1A1SMN1; SMN2MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 US disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA ALDH1A1 3541/4885SMN1; SMN2 3394/4885MAPT 3261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.